Primary and Secondary Hepatic Lymphomas Diagnosed by Image-Guided Fine-Needle Aspiration

Swadley, Matthew J.; Deliu, Matea; Mošunjac, Marina; Gunthel, Clifford J.; Nguyen, Minh Ly; Hanley, Krisztina

doi:10.1309/ajcpe58escqdzfkx

Cited by 15 publications

(12 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…DLBCL comprises 33% of all NHL,36 and 46% to 96% of PHL cases 6,9,10,14. Hepatic DLBCL accounted for approximately 6% of all primary extranodal DLBCL 37.…”

Section: Discussionmentioning

confidence: 99%

“…Based on liver infiltration, PHL can be subdivided into uninodular (39–42%), multinodular (50–55%), and diffuse (6–8%) types 6,9. Diffuse liver involvement of PHL is usually observed in immuno-compromised patients,10 such as human immunodeficiency virus (HIV) or liver diseases 11. Among 205 liver biopsies with lymphoma, 45% was diffuse large B cell lymphoma (DLBCL), and 12% was T cell lymphoma 12…”

Section: Introductionmentioning

confidence: 99%

“…It seems that PHL outcomes are not affected by presence of HCV infection6 and regress with HCV eradication 16. Furthermore, HIV was reported in 40% to 75% of PHL cases,10,14 and these patients have a worse prognosis 11…”

Section: Introductionmentioning

confidence: 99%

“…Liver biopsy is the most valuable tool for diagnosis 10,14. Clinical presentation of PHL is nonspecific and includes such symptoms as fever, loss of weight, night sweats, abdominal pain, jaundice and hepatomegaly.…”

Section: Introductionmentioning

confidence: 99%

“…To date, fewer than 400 PHL cases have been reported in the worldwide literature3,7,8,18,21,25,29–31 and large case series 6,9,10,14,32…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Non-Hodgkin Lymphoma of the Liver: A US Population-based Analysis

El-Fattah

2017

Journal of Clinical and Translational Hepatology

View full text Add to dashboard Cite

Background and Aims: Non-Hodgkin lymphoma (NHL) of the liver is a rare lymphoid malignancy, accounting for less than 1% of extranodal lymphomas.Methods: I conducted an analysis of the U.S Surveillance, Epidemiology, and End Results (SEER) database to evaluate the histological subtypes and the survival outcomes of 785 cases with hepatic NHL between 1973 and 2012.Results: There were 785 of 312 459 cases with NHL had a first primary hepatic NHL (0.25%). Of the total 785 cases, the median age at diagnosis was 61 years (range 3–95 years) and male-female ratio of 1.7:1. The most common subtype was diffuse large B cell lymphoma (63.2%). In all patients, the median overall survival (OS) was 33 months (95%CI, 22–48 months). The 5-year OS rate for indolent B-cell NHLs was 62%, compared with 44% for an aggressive B-cell NHLs and 42% for T-cell NHLs. The median OS improved from 19 months in patients diagnosed in a period 1996–2000 to 60 months when diagnosed between 2006 and 2012 (p < .001). In a multivariable Cox regression analysis, the age ≥80 years (adjusted hazard ratio [aHR] 3.21, p < .001), male gender (aHR 1.26, p = .02), Black race (aHR, 1.70, p < .001), and T-cell NHL variants (aHR 1.73, p = .03) were unfavourable prognostic factors.Conclusion: NHL of the liver comprises about 0.3% of all NHLs and survival was improved in the recent calendar period.

show abstract

“…DLBCL comprises 33% of all NHL,36 and 46% to 96% of PHL cases 6,9,10,14. Hepatic DLBCL accounted for approximately 6% of all primary extranodal DLBCL 37.…”

Section: Discussionmentioning

confidence: 99%